Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:11:12.960Z.
Calculation as of: 2026-10-06T14:11:12.960Z.
Quote observation: 2026-10-06T14:10:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 370e13d786cc28e63fbc6719e554b7ac483294971c86eef7c80c09e39811c756
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$719.62M
EV/EBIT Ratio
N/A
TTM Avg
877.08x
3Y Avg
871.89x
5Y Avg
871.89x
Market Cap
$762.81M
EV/EBIT Ratio
N/A
TTM Avg
501.20x
3Y Avg
422.57x
5Y Avg
422.57x
Market Cap
$769.83M
EV/EBIT Ratio
N/A
TTM Avg
957.13x
3Y Avg
957.13x
5Y Avg
957.13x
Market Cap
$716.11M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$777.34M
EV/EBIT Ratio
N/A
TTM Avg
15.22x
3Y Avg
6.50x
5Y Avg
6.50x
Market Cap
$715.49M
EV/EBIT Ratio
9.11x
TTM Avg
12.78x
3Y Avg
12.26x
5Y Avg
15.40x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $740.03M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $745.42M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.21M | N/A | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $719.62M | N/A | 877.08x | 871.89x | 871.89x |
| Cytek Biosciences, Inc. (CTKB)vs › | $762.81M | N/A | 501.20x | 422.57x | 422.57x |
| Geron Corporation (GERN)vs › | $769.83M | N/A | 957.13x | 957.13x | 957.13x |
| Anteris Technologies Global Corp. (AVR)vs › | $716.11M | N/A | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $777.34M | N/A | 15.22x | 6.50x | 6.50x |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.49M | 9.11x | 12.78x | 12.26x | 15.40x |
| Achieve Life Sciences, Inc. (ACHV)vs › | $715.02M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
